OCC2025凸显人工智能发展赋能心血管学科诊疗

Core Insights - The 19th Oriental Cardiovascular Conference (OCC2025) in Shanghai introduced the "CardioMind" model, which excels in multimodal data integration, deep reasoning, and diagnosing complex rare diseases [1][3][6] - The model demonstrated its capabilities through a simulated consultation, accurately diagnosing hereditary hemorrhagic telangiectasia type II, a rare clinical condition [3][6] Group 1: Model Features and Capabilities - "CardioMind" utilizes a general base model trained on extensive medical data, including guidelines and clinical trials, enabling a fully automated process from history collection to diagnostic assistance [6] - The model's "slow thinking" and deep reasoning mechanisms aim to reduce misdiagnoses caused by incomplete information, enhancing diagnostic accuracy [6] - Continuous learning and updates are integral to the model, ensuring it remains current with medical advancements [6] Group 2: Expert Insights and Applications - Experts highlighted the potential of artificial intelligence (AI) to optimize healthcare resource allocation and improve accessibility to medical services [6] - The accuracy and reliability of large models depend on the quality of training data, and challenges such as patient trust in digital doctors and compliance with ethical and regulatory standards must be addressed [6] - The conference emphasized the integration of big data, AI, and digital therapies into academic exchanges, reflecting a commitment to high-quality development in cardiovascular disease prevention and treatment [6] Group 3: AI in Clinical Practice - Demonstrations of AI in complex coronary interventions showcased its ability to integrate various imaging data, enhancing precision in procedures for patients with chronic total occlusions [9] - AI is expected to significantly expand physicians' knowledge bases, improve clinical skills, and accelerate the learning curve from junior to senior doctors [9] - The role of AI extends beyond data analysis to include target discovery, small molecule compound design, and optimization of clinical trials, marking it as an indispensable tool for current and future researchers [10]